Startups
Six months after bagging $115 million in a Series B financing round, Talaris Therapeutics is aiming to raise another $100 million through in initial public offering. It’s one of three companies joining in the flurry of IPOs this week.
Investment funds continue springing up into life sciences companies across the globe. Here’s where the money’s being planted this week.
Several companies launched with Series A financing rounds today. Read on for details.
Common stock in the new combined company, Tango Therapeutics, Inc., will soon be listed on Nasdaq under ticker “TNGX.”
Mayo Clinic announced Wednesday that it has launched two new tech venture companies designed to harness artificial intelligence (AI) and medical algorithms and create “software as medical devices” that clinicians can use to improve treatment across different diseases.
ValenzaBio plans to use the new financing to advance pipeline programs into autoantibody-mediated diseases, thyroid eye disease, inflammatory disorders and other therapeutic areas.
The wave of biopharma companies going public continues with two more companies setting sights on publicly trading on a stock exchange. Reneo Pharmaceuticals and VectivBio will both begin trading on the Nasdaq this week.
Eleven months after launching with $60 million in hand, Ventus Therapeutics has raised another $100 million to drive its pipeline toward the clinic.
April springs up with showers of cash for these life sciences companies.
Philadelphia-based Mineralys Therapeutics launched today with a $40 million Series A round to move its clinical asset, MLS-101, into Phase II testing for hypertension.
PRESS RELEASES